BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Safarov T, Kiran B, Bagirova M, Allahverdiyev AM, Abamor ES. An overview of nanotechnology-based treatment approaches against Helicobacter Pylori. Expert Review of Anti-infective Therapy 2019;17:829-40. [DOI: 10.1080/14787210.2019.1677464] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Milewska S, Niemirowicz-Laskowska K, Siemiaszko G, Nowicki P, Wilczewska AZ, Car H. Current Trends and Challenges in Pharmacoeconomic Aspects of Nanocarriers as Drug Delivery Systems for Cancer Treatment. Int J Nanomedicine 2021;16:6593-644. [PMID: 34611400 DOI: 10.2147/IJN.S323831] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Faisal S, Abdullah, Jan H, Shah SA, Shah S, Rizwan M, Zaman N, Hussain Z, Uddin MN, Bibi N, Khattak A, Khan W, Iqbal A, Idrees M, Masood R. Bio-Catalytic Activity of Novel Mentha arvensis Intervened Biocompatible Magnesium Oxide Nanomaterials. Catalysts 2021;11:780. [DOI: 10.3390/catal11070780] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
3 Zhang J, Chen Z, Kong J, Liang Y, Chen K, Chang Y, Yuan H, Wang Y, Liang H, Li J, Mao M, Li J, Xing G. Fullerenol Nanoparticles Eradicate Helicobacter pylori via pH-Responsive Peroxidase Activity. ACS Appl Mater Interfaces 2020. [PMID: 32486636 DOI: 10.1021/acsami.0c05509] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Pinho AS, Seabra CL, Nunes C, Reis S, L Martins MC, Parreira P. Helicobacter pylori biofilms are disrupted by nanostructured lipid carriers: A path to eradication? J Control Release 2022;348:489-98. [PMID: 35654169 DOI: 10.1016/j.jconrel.2022.05.050] [Reference Citation Analysis]
5 de Souza MPC, de Camargo BAF, Spósito L, Fortunato GC, Carvalho GC, Marena GD, Meneguin AB, Bauab TM, Chorilli M. Highlighting the use of micro and nanoparticles based-drug delivery systems for the treatment of Helicobacter pylori infections. Crit Rev Microbiol 2021;47:435-60. [PMID: 33725462 DOI: 10.1080/1040841X.2021.1895721] [Reference Citation Analysis]
6 Chaves de Souza MP, de Mattos NH, Pedreiro LN, Boni FI, Dos Santos Ramos MA, Bauab TM, Gremião MPD, Chorilli M. Design of Mucoadhesive Nanostructured Polyelectrolyte Complexes Based on Chitosan and Hypromellose Phthalate for Metronidazole Delivery Intended to the Treatment of Helicobacter pylori Infections. Pharmaceutics 2020;12:E1211. [PMID: 33327588 DOI: 10.3390/pharmaceutics12121211] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Cardos IA, Zaha DC, Sindhu RK, Cavalu S. Revisiting Therapeutic Strategies for H. pylori Treatment in the Context of Antibiotic Resistance: Focus on Alternative and Complementary Therapies. Molecules 2021;26:6078. [PMID: 34641620 DOI: 10.3390/molecules26196078] [Reference Citation Analysis]